alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › cholinesterase-inhibitors

cholinesterase-inhibitors

17 studies tagged cholinesterase-inhibitors, dated 1998-05-01 to 2020-01-28. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease 2020-01-28
  2. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials 2018-12-27
  3. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease 2018-09-13

Studies

17 studies carry this tag.

Date range

1998 to 2020

Top journals

  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2
  • Alzheimer's research & therapy 1
  • Archives of internal medicine 1
  • Biological psychiatry 1
  • Current medicinal chemistry 1

16 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Expert opinion on drug safety 2020-01-28 Treatments

    Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders with a prevalence in the US of about 5.7 million in 2018.

  2. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. Alzheimer's research & therapy 2018-12-27 Treatments

    Pharmacological interventions have beneficial effects on cognition, function, and global changes, but not on neuropsychiatric symptoms, through current network meta-analysis.

  3. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. European journal of medicinal chemistry 2018-09-13 Treatments

    Alzheimer's disease (AD) is one of the most common neurodegenerative disorders in elderly people.

  4. Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients

    ✓ Peer-reviewed alzhub usefulness score 86 out of 100. The international journal of neuropsychopharmacology 2017-07-01 Treatments

    Intervention- and patient-related factors modify the effect of cholinesterase inhibitors in patients with Alzheimer's disease.

  5. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. PloS one 2015-12-07 Treatments

    This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia.

  6. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. European heart journal 2013-06-04 Treatments

    Cholinesterase inhibitor use was associated with a reduced risk of MI and death in a nationwide cohort of subjects diagnosed with Alzheimer's dementia.

  7. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pharmacology & therapeutics 2011-12-16 Treatments

    Alzheimer's disease (AD) is the most common cause of memory impairment and dementia in the elderly.

  8. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current medicinal chemistry 2007-01-01 Treatments

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) which is the most common cause of dementia in the elderly.

  9. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Archives of internal medicine 2005-04-01 Treatments

    Use of cholinesterase inhibitors is associated with an increased risk of receiving an anticholinergic drug to manage urinary incontinence.

  10. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuro-Signals 2005-01-01 Treatments

    Huperzine A (HupA), isolated from Chinese herb Huperzia serrata, is a potent, highly specific and reversible inhibitor of acetylcholinesterase.

  11. Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2004-07-01 Treatments

    A systematic program of cognitive rehabilitation can result in maintained improvement in performance on specific cognitive and functional tasks in mildly impaired AD patients.

  12. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2003-03-01 Treatments

    Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with Alzheimer disease (AD) and are the only class of drugs approved by the Food and Drug Administration (FDA) for treatment of this condition.

  13. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Biological psychiatry 2001-02-01 Treatments

    Despite the proven efficacy of acetylcholinesterase inhibitors in Alzheimer's disease, there is a need for new and more effective treatments.

  14. Cholinesterase inhibitors for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Drugs 2001-01-01 Treatments

    Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and has become an urgent public health problem in most areas of the world.

  15. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Methods and findings in experimental and clinical pharmacology 2000-10-01 Treatments

    This study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) of donepezil and some other cholinesterase (ChE) inhibitors which have been developed for the treatment of Alzheimer's disease.

  16. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Drugs of today (Barcelona, Spain : 1998) 2000-07-01 Drug development

    Potential therapeutic strategies for AD treatment include palliative treatment with nonspecific neuroprotecting agents, symptomatic treatment with psychotropic drugs for noncognitive symptoms, cognitive treatment with cognition enhancers, substitutive treatment with cholinergic enhancers to improve memory deficits, multifactorial treatment using several drugs in combination and etiopathogenic treatment designed to regulate molecular factors potentially associated with AD pathogenesis.

  17. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurochemistry international 1998-05-01 Treatments

    This review starts with an historical background of the pharmacological development of tacrine almost fifty years ago (1949).

All topic tags with their study counts